TOLECTIN 600
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOLECTIN 600 (TOLECTIN 600).
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
| Metabolism | Hepatic metabolism primarily via CYP2C9 and CYP2C8; forms inactive metabolites. |
| Excretion | Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%) |
| Half-life | Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 0.15-0.2 L/kg; indicates distribution mainly into extracellular fluid. |
| Bioavailability | Oral: approximately 90-100% (well absorbed with minimal first-pass metabolism). |
| Onset of Action | Oral: 30-60 minutes for analgesic effect. |
| Duration of Action | Oral: 4-6 hours (analgesic); anti-inflammatory effect may persist longer with repeated dosing. |
| Molecular Weight | 257.3 |
600 mg orally three times daily; maximum 1800 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR < 10-30 mL/min: cautious use, reduce dose by 50% if necessary; GFR < 10 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | Not recommended for children under 18 years of age. |
| Geriatric use | Start at lower end of dosing range, consider 400 mg three times daily, monitor renal function and gastrointestinal tolerance. |
| 1st trimester | Avoid use in first trimester due to potential teratogenic effects; NSAIDs may increase risk of cardiac malformations. |
| 2nd trimester | Use with caution; may cause oligohydramnios and premature ductus arteriosus constriction when used long-term. |
| 3rd trimester | Avoid use in third trimester; risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for TOLECTIN 600 (TOLECTIN 600).
| Placental transfer | Tolmetin crosses the placenta; detectable levels in fetal serum, but extent of transfer is not fully quantified. |
| Breastfeeding | Tolmetin is excreted into breast milk in small amounts; however, due to potential adverse effects on infant renal function and gastrointestinal system, use with caution and monitor infant for side effects. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
| Serious Effects |
Hypersensitivity to tolmetin or any other NSAIDHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsActive peptic ulcer diseaseHistory of gastrointestinal bleeding or perforation related to previous NSAID therapySevere heart failure (NYHA Class IV)Triple therapy: concurrent use of ACE inhibitors, diuretics, and NSAIDsAdvanced renal disease
| Precautions | Cardiovascular risk (including MI and stroke); gastrointestinal risk (bleeding, ulceration, perforation); renal toxicity (including papillary necrosis and renal failure); hepatic toxicity; anaphylactoid reactions; elevated liver enzymes; anemia; fluid retention and edema; hypertension. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C (pre-2015) for NSAIDs; Category D from 30 weeks gestation onward. First trimester: possible increased risk of miscarriage and cardiac defects. Second trimester: avoid prolonged use due to risk of oligohydramnios. Third trimester: contraindicated due to risk of premature ductus arteriosus closure and persistent pulmonary hypertension in the neonate. |
| Fetal Monitoring | Monitor amniotic fluid volume via ultrasound if prolonged use; fetal echocardiography in third trimester if exposure occurs; assess for ductus arteriosus constriction. Monitor maternal renal function, blood pressure, and signs of bleeding. |
| Fertility Effects | May impair female fertility by interfering with ovulation via prostaglandin synthesis inhibition; effects are reversible upon discontinuation. No known effects on male fertility. |
| Alcohol may increase risk of GI bleeding. No specific food restrictions; but taking with meals or milk can reduce GI irritation. |
| Clinical Pearls | TOLECTIN 600 (tolmetin sodium) is a nonsteroidal anti-inflammatory drug (NSAID) used for rheumatoid arthritis and osteoarthritis. Monitor renal function and hepatic enzymes regularly. Avoid in patients with aspirin-sensitive asthma. Use lowest effective dose for shortest duration due to cardiovascular and GI risks. May cause false positive urinary albumin tests using sulfosalicylic acid. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Avoid alcohol while taking this medication. · Notify your doctor if you experience black stools, persistent stomach pain, or easy bruising. · Do not exceed prescribed dose; risk of heart attack or stroke increases with higher doses. · Inform all healthcare providers you are taking tolmetin before any surgery. |